v3.26.1
Document and Entity Information - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Mar. 23, 2026
Jun. 30, 2025
Cover [Abstract]      
Entity Public Float     $ 84,600
Entity Registrant Name Entera Bio Ltd.    
Document Type 10-K    
Document Period End Date Dec. 31, 2025    
Entity Central Index Key 0001638097    
Current Fiscal Year End Date --12-31    
Entity Filer Category Non-accelerated Filer    
Amendment Flag false    
Entity Current Reporting Status Yes    
Entity Common Stock, Shares Outstanding   46,622,239  
Document Fiscal Year Focus 2025    
Document Fiscal Period Focus FY    
Entity Shell Company false    
Entity Small Business true    
Entity Interactive Data Current Yes    
Entity Emerging Growth Company false    
Entity Incorporation, State or Country Code L3    
Entity Address, Address Line One Kiryat Hadassah    
Entity Address, Address Line Two Minrav Building - Fifth Floor    
Entity Address, City or Town Jerusalem    
Entity Address, Postal Zip Code 9112002    
Entity Address, Country IL    
City Area Code 972    
Local Phone Number 2-532-7151    
Document Transition Report false    
Entity File Number 001-38556    
Entity Tax Identification Number 00-0000000    
Trading Symbol ENTX    
Security Exchange Name NASDAQ    
Title of 12(b) Security Ordinary shares    
Entity Voluntary Filers No    
Entity Well-known Seasoned Issuer No    
Document Annual Report true    
Auditor Name Kesselman & Kesselman    
Auditor Location Tel-Aviv, Israel    
Auditor Firm ID 1309    
Document Financial Statement Error Correction [Flag] false    
Auditor Opinion
Opinion on the Financial Statements
 
We have audited the accompanying consolidated balance sheets of Entera Bio Ltd. and its subsidiary (the “Company”) as of December 31, 2025 and 2024, and the related consolidated statements of operations, changes in shareholders' equity and cash flows for the years then ended, including the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.
   
ICFR Auditor Attestation Flag false